<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="267ccbb4-3f97-4caf-a4a7-7bb9ae9e3d38"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use MESALAMINE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for MESALAMINE DELAYED-RELEASE TABLETS.<br/>
         <br/>
      </content>
      <content styleCode="bold">MESALAMINE delayed-release tablets, for oral use<br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 1987</content>
   </title>
   <effectiveTime value="20250327"/>
   <setId root="ba1e3bd4-fbe0-46a5-961e-167ccb09672c"/>
   <versionNumber value="24"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119723554" root="1.3.6.1.4.1.519.1"/>
            <name>Actavis Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="8451ab43-a5dd-492c-8339-0a983e4a0022"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250327"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0591-2245" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Mesalamine</name>
                        <formCode code="C42905" displayName="TABLET, DELAYED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Mesalamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="1.2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4Q81I59GXC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MESALAMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4Q81I59GXC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MESALAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5KY68S2577" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RDH86HJV5Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K90</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="120"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0591-2245-22" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180326"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203817" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180326"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" displayName="red" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>red-brown</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">WPI;2245</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_559265cb-779b-4415-8d3a-ab325b2b362c">
               <id root="459f4f93-4dee-4c87-885d-36539aceb9c0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Mesalamine delayed-release tablets are indicated for the: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.</item>
                     <item>Treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.</item>
                  </list>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Mesalamine is an aminosalicylate indicated for the: </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. (<linkHtml href="#LINK_559265cb-779b-4415-8d3a-ab325b2b362c">1</linkHtml>)</item>
                           <item>Treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. (<linkHtml href="#LINK_559265cb-779b-4415-8d3a-ab325b2b362c">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">
               <id root="bbfcc2c0-c696-4a6c-8e90-2ee97b5df6a8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Evaluate renal function prior to initiation of mesalamine delayed-release tablets and periodically while on therapy.</item>
                     <item>Swallow mesalamine delayed-release tablets whole; do not split or crush.</item>
                     <item>Administer mesalamine delayed-release tablets with food <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_618cf8e2-ee7b-4241-a4bb-610f05fa3416">12.3</linkHtml>)]</content>.</item>
                     <item>Drink an adequate amount of fluids <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Adults</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>The recommended dosage for the induction of remission in adult patients with mildly to moderately active ulcerative colitis is 2.4 g to 4.8 g (two to four 1.2 g tablets) taken once daily.</item>
                     <item>The recommended dosage for the maintenance of remission is 2.4 g (two 1.2 g tablets) taken once daily.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Pediatric Patients</content>
                  </paragraph>
                  <paragraph> The recommended dosage for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg who can swallow tablets whole is shown in Table 1:</paragraph>
                  <table width="800px" cellspacing="0" cellpadding="5" border="0">
                     <caption>Table 1: Recommended Dosage of Mesalamine Delayed-Release Tablets for the Treatment of Mildly to Moderately Active Ulcerative Colitis in Pediatric Patients Weighing at least 24 kg</caption>
                     <col width="169.15pt"/>
                     <col width="291.1pt"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Weight of Pediatric Patient</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Once Daily </content>
                                 <content styleCode="bold">Mesalamine Delayed-Release Tablets</content>
                                 <content styleCode="bold"> Dosage</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Week 0 to Week 8</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">After Week 8</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>24 kg to 35 kg</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>2.4 g</paragraph>
                              <paragraph>(two 1.2 g tablets)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>1.2 g</paragraph>
                              <paragraph>(one 1.2 g tablet)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Greater than 35 kg to 50 kg</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>3.6 g</paragraph>
                              <paragraph>(three 1.2 g tablets)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>2.4 g</paragraph>
                              <paragraph>(two 1.2 g tablets)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Greater than 50 kg</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>4.8 g</paragraph>
                              <paragraph>(four 1.2 g tablets)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>2.4 g</paragraph>
                              <paragraph>(two 1.2 g tablets)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Evaluate renal function prior to initiation of mesalamine delayed-release tablets and periodically while on therapy. (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>, <linkHtml href="#LINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>)</item>
                           <item>Swallow mesalamine delayed-release tablets whole; do not split or crush. (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)</item>
                           <item>Administer mesalamine delayed-release tablets with food. (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)</item>
                           <item>Drink an adequate amount of fluids. (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>, <linkHtml href="#LINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage in Adults</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics">For induction of remission</content>: 2.4 g to 4.8 g (two to four 1.2 g tablets) once daily. (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">For maintenance of remission</content>: 2.4 g (two 1.2 g tablets) once daily. (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage in Pediatric Patients</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg who can swallow tablets whole is shown below: (<linkHtml href="#LINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)</item>
                        </list>
                        <table width="500px" cellspacing="0" cellpadding="5" border="0">
                           <col width="99.2pt"/>
                           <col width="149.95pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Weight of Pediatric Patient</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Once Daily Mesalamine Delayed-Release Tablets Dosage</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Week 0 to Week 8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>After Week 8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>24 kg to 35 kg</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.4 g</paragraph>
                                    <paragraph>(two 1.2 g tablets)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1.2 g</paragraph>
                                    <paragraph>(one 1.2 g tablet)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 35 kg to 50 kg</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3.6 g</paragraph>
                                    <paragraph>(three 1.2 g tablets)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.4 g</paragraph>
                                    <paragraph>(two 1.2 g tablets)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 50 kg</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4.8 g</paragraph>
                                    <paragraph>(four 1.2 g tablets)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.4 g</paragraph>
                                    <paragraph>(two 1.2 g tablets)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_0f285c1b-866a-4c30-ad98-2a439448ec17">
               <id root="92efc6d2-9dd3-453f-8170-ec159bb99bb3"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>The red-brown, oval shaped, delayed-release, coated tablet containing 1.2 g mesalamine, USP is imprinted with “<content styleCode="bold">WPI 2245</content>” in black ink on one side and plain on the other side.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Delayed-Release Tablets: 1.2 g (<linkHtml href="#LINK_0f285c1b-866a-4c30-ad98-2a439448ec17">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_494ffc27-130d-41fb-9170-7d79a83b16f5">
               <id root="f004c907-ba3e-44a4-9171-80709c9ef01c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Mesalamine is contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or to any of the ingredients of mesalamine delayed-release tablets <content styleCode="italics">[</content>
                     <content styleCode="italics">see </content>
                     <content styleCode="italics">Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_77245a53-50d3-42e8-a043-e9202711b091">5.3</linkHtml>), Adverse Reactions (<linkHtml href="#www.splportal.comLINK_88415080-889c-487e-9988-7a3b0fb3036f">6.2</linkHtml>), Description (<linkHtml href="#www.splportal.comLINK_1e9604e1-48c5-4b27-b9e9-5e728bd79181">11</linkHtml>)</content>
                     <content styleCode="italics">].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known or suspected hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of mesalamine delayed-release tablets. (<linkHtml href="#LINK_494ffc27-130d-41fb-9170-7d79a83b16f5">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_525a2f54-b55c-4e1b-9c36-32cebdc32c52">
               <id root="6c272e64-7d1f-4863-9a4b-b37a2f1463bf"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Renal Impairment</content>: Assess renal function at the beginning of treatment and periodically during treatment. Evaluate the risks and benefits of mesalamine in patients with known renal impairment or taking nephrotoxic drugs. Discontinue mesalamine if renal function deteriorates while on therapy. (<linkHtml href="#LINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>, <linkHtml href="#LINK_c2007783-4b65-4436-8554-b474a37c113a">7.1</linkHtml>, <linkHtml href="#LINK_40adab2c-116a-4eb4-b62e-a033fad0cc03">8.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Mesalamine-Induced Acute Intolerance Syndrome</content>: Symptoms may be difficult to distinguish from an ulcerative colitis exacerbation. Monitor for worsening symptoms while on treatment. Discontinue treatment if acute intolerance syndrome is suspected. (<linkHtml href="#LINK_69f9eecd-e0d2-493d-88e8-47ea95ca44a4">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions, including myocarditis and pericarditis</content>: Evaluate patients immediately and discontinue mesalamine if a hypersensitivity reaction is suspected. (<linkHtml href="#LINK_77245a53-50d3-42e8-a043-e9202711b091">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatic Failure</content>: Evaluate the risks and benefits of using mesalamine in patients with known liver impairment. (<linkHtml href="#LINK_9269061b-686e-453d-8fbb-25b501e75dff">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Severe Cutaneous Adverse Reactions</content>: Discontinue at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation. (<linkHtml href="#LINK_4ab65921-2858-423a-bd98-39f3702c03c0">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Upper Gastrointestinal Tract Obstruction</content>: Avoid in patients with pyloric stenosis or other organic or functional obstruction. (<linkHtml href="#LINK_7eefc9a2-09ca-4d84-91d1-6a26feccc7fa">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Photosensitivity</content>: Advise patients with pre-existing skin conditions to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors. (<linkHtml href="#LINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Nephrolithiasis</content>: Cases of nephrolithiasis have been reported with the use of mesalamine. Mesalamine-containing stones are undetectable by standard radiography or computed tomography (CT). Ensure adequate hydration during treatment. (<linkHtml href="#LINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Interference with Laboratory Tests</content>: Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection. (<linkHtml href="#LINK_a9ca08b4-e79a-46e7-bf9a-9989175cf0bf">5.9</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">
                     <id root="836dda3c-e885-485e-b9ea-098170dc8f61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Renal Impairment</title>
                     <text>
                        <paragraph>Renal impairment, including minimal change disease, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products such as mesalamine delayed-release tablets that contain mesalamine or are converted to mesalamine. In animal studies, the kidney was the principal organ of mesalamine toxicity <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_88415080-889c-487e-9988-7a3b0fb3036f">6.2</linkHtml>), Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_521db0db-ac99-4e31-ae36-5e2c99602b4a">13.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Evaluate renal function prior to initiation of mesalamine therapy and periodically while on therapy. Evaluate the risks and benefits of using mesalamine in patients with known renal impairment, history of renal disease, or taking concomitant nephrotoxic drugs. Discontinue mesalamine if renal function deteriorates while on therapy <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_c2007783-4b65-4436-8554-b474a37c113a">7.1</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_40adab2c-116a-4eb4-b62e-a033fad0cc03">8.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_69f9eecd-e0d2-493d-88e8-47ea95ca44a4">
                     <id root="ee488db5-c1ff-4141-a5a6-fcfbed7a6903"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Mesalamine-Induced Acute Intolerance Syndrome</title>
                     <text>
                        <paragraph>Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of ulcerative colitis. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain, and bloody diarrhea, and sometimes fever, headache, and rash. Monitor patients closely for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with mesalamine.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_77245a53-50d3-42e8-a043-e9202711b091">
                     <id root="5769366c-c8a9-4f73-bdc2-fc9599c08acf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Hypersensitivity reactions have been reported in patients taking sulfasalazine. Some of these patients may have a similar reaction to mesalamine delayed-release tablets or to other compounds that contain or are converted to mesalamine.</paragraph>
                        <paragraph>As with sulfasalazine, mesalamine-induced hypersensitivity reactions may present as internal organ involvement, including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis, and hematologic abnormalities. Evaluate patients immediately if signs or symptoms of a hypersensitivity reaction are present. Discontinue mesalamine delayed-release tablets if an alternative etiology for the signs or symptoms cannot be established.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9269061b-686e-453d-8fbb-25b501e75dff">
                     <id root="930e7433-81b9-4680-9a34-eb16342a0147"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 	Hepatic Failure</title>
                     <text>
                        <paragraph>There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine. Evaluate the risks and benefits of using mesalamine in patients with known liver impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4ab65921-2858-423a-bd98-39f3702c03c0">
                     <id root="4c892703-605a-40e6-bc36-41067424d4af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Severe Cutaneous
Adverse Reactions</title>
                     <text>
                        <paragraph>Severe cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of mesalamine <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_88415080-889c-487e-9988-7a3b0fb3036f">6.2</linkHtml>)]</content>. Discontinue mesalamine delayed-release tablets at the first appearance of signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7ea758a3-f44f-4eb8-afeb-0da59787fca7">
                     <id root="156e7c74-6ab7-48c3-8a9e-454ed3e1b4da"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Upper Gastrointestinal Tract Obstruction</title>
                     <text>
                        <paragraph>Pyloric stenosis or other organic or functional obstruction in the upper gastrointestinal tract may cause prolonged gastric retention of mesalamine, which would delay mesalamine release in the colon. Avoid mesalamine in patients at risk of upper gastrointestinal tract obstruction.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7eefc9a2-09ca-4d84-91d1-6a26feccc7fa">
                     <id root="8bc69159-631c-4a77-be9f-acb6ea8e3ad8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Photosensitivity</title>
                     <text>
                        <paragraph>Patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema have reported more severe photosensitivity reactions. Advise patients to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6ffce658-783e-482e-94a9-a9c52c855eca">
                     <id root="757fac08-a5bb-4e35-8c01-42fc2759d648"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Nephrolithiasis</title>
                     <text>
                        <paragraph>Cases of nephrolithiasis have been reported with the use of mesalamine, including stones with a 100% mesalamine content. Mesalamine-containing stones are radiotransparent and undetectable by standard radiography or computed tomography (CT). Ensure adequate hydration during treatment with mesalamine.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a9ca08b4-e79a-46e7-bf9a-9989175cf0bf">
                     <id root="729822da-85ea-4c24-84ed-57bb34fd5283"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Interference with Laboratory Tests</title>
                     <text>
                        <paragraph>Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and the main metabolite of mesalamine, N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA). Consider an alternative, selective assay for normetanephrine.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e00aaf2b-a655-4fb5-8b8e-ece4fd0b0b68">
               <id root="14bbcded-d833-4291-a37a-34666876f73e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Renal impairment, including renal failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>)]</content>
                     </item>
                     <item>Mesalamine-induced acute intolerance syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_69f9eecd-e0d2-493d-88e8-47ea95ca44a4">5.2</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_77245a53-50d3-42e8-a043-e9202711b091">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hepatic failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_9269061b-686e-453d-8fbb-25b501e75dff">5.4</linkHtml>)]</content>
                     </item>
                     <item>Severe cutaneous adverse reactions <content styleCode="italics">
                           <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4ab65921-2858-423a-bd98-39f3702c03c0">5.5</linkHtml>)]</content>
                        </content>
                     </item>
                     <item>Upper gastrointestinal tract obstruction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7ea758a3-f44f-4eb8-afeb-0da59787fca7">5.6</linkHtml>)] </content>
                     </item>
                     <item>Photosensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7eefc9a2-09ca-4d84-91d1-6a26feccc7fa">5.7</linkHtml>)] </content>
                     </item>
                     <item>Nephrolithiasis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)] </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions in:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>adults (≥2%) are headache, flatulence, liver function test abnormal, abdominal pain, and diarrhea. (<linkHtml href="#LINK_28536af0-f3bb-467b-ab42-6ee1a3b59461">6.1</linkHtml>)</item>
                           <item>pediatric patients (≥5%) are abdominal pain, upper respiratory tract infection, vomiting, anemia, headache, and viral infection. (<linkHtml href="#LINK_28536af0-f3bb-467b-ab42-6ee1a3b59461">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="bold">
                                 <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_28536af0-f3bb-467b-ab42-6ee1a3b59461">
                     <id root="84941a8c-0101-4039-baab-f58aaa48c1e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Induction</content>
                        </paragraph>
                        <paragraph> The most common adverse reactions occurring in at least 1% of mesalamine- or placebo-treated adult patients with mildly to moderately active ulcerative colitis in two eight-week, randomized, double-blind, placebo-controlled trials (Study 1 and Study 2) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_14625eff-0d66-4d9f-9a29-601254cd684b">14.1</linkHtml>)] </content>are listed in Table 2.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 2: Adverse Reactions* in Two Eight-Week, Placebo-Controlled Trials of Induction Therapy (Study 1 and Study 2) in Adults with Mildly to Moderately Active Ulcerative Colitis</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Mesalamine</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">2.4 g once daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=177)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Mesalamine</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">4.8 g once daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=179)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=179)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Flatulence</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Liver Function Test Abnormal</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Alopecia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>&lt;1%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <paragraph>*Reported in at least 1% of patients in at least one mesalamine group and greater than placebo</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Pancreatitis occurred in less than 1% of patients during induction in clinical trials and resulted in discontinuation of therapy with mesalamine in patients experiencing this event.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Maintenance of Remission</content>
                        </paragraph>
                        <paragraph>A mesalamine dosage of 2.4 g/day, administered as either 1.2 g twice daily or 2.4 g once daily, was evaluated for safety in three maintenance trials in patients with mildly to moderately active ulcerative colitis: a 6-month double-blind, active-controlled study (Study 3) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_14625eff-0d66-4d9f-9a29-601254cd684b">14.1</linkHtml>)] </content>and two 12- to 14-month open-label studies. The most common adverse reactions with mesalamine in these maintenance trials are listed in Table 3.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 3: Adverse Reactions* in Three Trials of Maintenance of Remission in Adults with Ulcerative Colitis</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Mesalamine</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">2.4 g/day<sup>†</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1082)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Liver function test abnormal</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abdominal pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abdominal distension</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Abdominal pain upper</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dyspepsia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Back pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Rash</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Arthralgia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Fatigue</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypertension</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <paragraph>
                                       <sup>*</sup>Reported in at least 1% of patients</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <paragraph>
                                       <sup>†</sup>Administered either as 1.2 g twice daily or 2.4 g once daily</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The following adverse reactions, presented by body system, were reported  in less than 1% of mesalamine-treated patients with ulcerative colitis in either induction or maintenance trials:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorder:</content> tachycardia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth Disorders: </content>ear pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> abdominal distention, colitis, diarrhea, flatulence, nausea, pancreatitis, rectal polyp, vomiting</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administrative Site Disorders:</content> asthenia, face edema, fatigue, pyrexia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations: </content>decreased platelet count</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>arthralgia, back pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content> dizziness, somnolence, tremor</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders: </content>pharyngolaryngeal pain</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> acne, prurigo, rash, alopecia, pruritus, urticaria</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders: </content>hypertension, hypotension</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatrics</content>
                        </paragraph>
                        <paragraph> Mesalamine was evaluated in 105 pediatric patients 5 through 17 years of age with mildly to moderately active ulcerative colitis <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_c10e39db-a6fe-4e9c-b720-60b58dc521ee">14.2</linkHtml>)]</content>. The adverse reaction profile was similar to that of adults. The most common adverse reactions reported in at least 5% of pediatric patients treated with mesalamine were: abdominal pain, upper respiratory tract infection, vomiting, anemia, headache, and viral infection.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_88415080-889c-487e-9988-7a3b0fb3036f">
                     <id root="03b25c18-f633-44fa-9307-46e892776faa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of mesalamine or other mesalamine-containing products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole: </content>lupus-like syndrome, drug fever</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders:</content> pericarditis, pericardial effusion, myocarditis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_77245a53-50d3-42e8-a043-e9202711b091">5.3</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>cholecystitis, gastritis, gastroenteritis, gastrointestinal bleeding, perforated peptic ulcer</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic: </content> jaundice, cholestatic jaundice, hepatitis, liver necrosis, liver failure, hepatotoxicity, Kawasaki-like syndrome including changes in liver enzymes</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic: </content>agranulocytosis, aplastic anemia</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="italics">Immune System Disorders: </content>
                           </content>anaphylactic reaction, angioedema</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders: </content>myalgia, lupus-like syndrome</paragraph>
                        <paragraph>
                           <content styleCode="italics">Neurological/Psychiatric: </content>peripheral neuropathy, Guillain-Barré syndrome, transverse myelitis, intracranial hypertension</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Disorders:</content> renal failure, interstitial nephritis, nephrogenic diabetes insipidus, nephrolithiasis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)]<br/>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="italics"> </content>Urine discoloration occurring ex-vivo caused by contact of mesalamine, including inactive metabolite, with surfaces or water treated with hypochlorite-containing bleach</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="italics">Respiratory, Thoracic and Mediastinal Disorders: </content>
                           </content>interstitial lung disease, hypersensitivity pneumonitis (including interstitial pneumonitis, allergic alveolitis, eosinophilic pneumonitis), pleurisy/pleuritis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin:</content> psoriasis, pyoderma gangrenosum, erythema nodosum, photosensitivity, SJS/TEN, DRESS, and AGEP <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4ab65921-2858-423a-bd98-39f3702c03c0">5.5</linkHtml>)]</content> </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urogenital:</content> reversible oligospermia</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_832263fe-4f41-4408-b6e0-adf5130bfa82">
               <id root="cd96ccc6-fbfe-4159-9fea-38627c3675ee"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7	DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Nephrotoxic Agents including NSAIDs</content>: Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions. (<linkHtml href="#LINK_c2007783-4b65-4436-8554-b474a37c113a">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Azathioprine or 6-Mercaptopurine</content>: Increased risk of blood dyscrasias; monitor complete blood cell counts and platelet counts. (<linkHtml href="#LINK_64c59764-d7eb-442d-a823-6b1b491340ac">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_c2007783-4b65-4436-8554-b474a37c113a">
                     <id root="9e8af8b9-1528-49e2-a114-62d06f162d65"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs</title>
                     <text>
                        <paragraph>The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs), may increase the risk of nephrotoxicity. Monitor patients taking nephrotoxic drugs for changes in renal function and mesalamine-related adverse reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_64c59764-d7eb-442d-a823-6b1b491340ac">
                     <id root="c8a8c968-3740-46e2-8585-47f0342427d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Azathioprine and 6-Mercaptopurine</title>
                     <text>
                        <paragraph>The concurrent use of mesalamine with azathioprine or 6-mercaptopurine and/or any other drugs known to cause myelotoxicity may increase the risk for blood disorders, bone marrow failure, and associated complications. If concomitant use of mesalamine and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_54d157a3-afd8-4d61-9291-96fdd4467627">
                     <id root="0ae7c888-dd78-4346-ad9e-1878de7343e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Interference with Urinary
Normetanephrine Measurements</title>
                     <text>
                        <paragraph>Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_a9ca08b4-e79a-46e7-bf9a-9989175cf0bf">5.9</linkHtml>)]</content>. Consider an alternative, selective assay for normetanephrine.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d89a4b10-3af7-42ab-bf83-72983b32f504">
               <id root="f54cfc83-923b-4b3b-acbd-c47082a35a45"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Geriatric Patients</content>: Increased risk of blood dyscrasias; monitor complete blood cell counts and platelet counts. (<linkHtml href="#LINK_b24e8ccc-ad42-4eb6-bf6a-68f72bd21d00">8.5</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d385ad6c-26ee-4217-a567-51542de9284b">
                     <id root="12f8a2f2-b48e-46a8-976b-6307f757d115"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Published data from meta-analyses, cohort studies, and case series on the use of mesalamine during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see Data</content>). There are adverse effects on maternal and fetal outcomes associated with ulcerative colitis in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. </paragraph>
                        <paragraph>In animal reproduction studies, there were no adverse developmental outcomes with administration of oral mesalamine during organogenesis to pregnant rats and rabbits at doses 1.8 and 2.9 times, respectively, the maximum recommended human dose <content styleCode="italics">(see Data)</content>. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated maternal and embryo/fetal risk </content>
                        </paragraph>
                        <paragraph>Published data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with ulcerative colitis. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2,500 g) infants, and small for gestational age at birth. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>Published data from meta-analyses, cohort studies, and case series on the use of mesalamine during early pregnancy (first trimester) and throughout pregnancy have not reliably informed an association of mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is no clear evidence that mesalamine exposure in early pregnancy is associated with an increased risk of major congenital malformations, including cardiac malformations. Published epidemiologic studies have important methodological limitations which hinder interpretation of the data, including inability to control for confounders, such as underlying maternal disease, maternal use of concomitant medications, and missing information on the dose and duration of use for mesalamine products. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Reproduction studies with mesalamine during organogenesis have been performed in rats at doses up to 1,000 mg/kg/day (1.8 times the maximum recommended human dose based on a body surface area comparison) and rabbits at doses up to 800 mg/kg/day (2.9 times the maximum recommended human dose based on a body surface area comparison) and have revealed no evidence of harm to the fetus due to mesalamine. </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7aaa972f-1a1b-4978-91f6-90b86f1a75cc">
                     <id root="c307ba23-cf19-4b96-b1c2-fdfd795896c9"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Data from published literature report the presence of mesalamine and its metabolite, N-acetyl-5-aminosalicylic acid in human milk in small amounts with relative infant doses (RID) of 0.1% or less for mesalamine <content styleCode="italics">(see Data)</content>. There are case reports of diarrhea in breastfed infants exposed to mesalamine <content styleCode="italics">(see Clinical Considerations)</content>. There is no information on the effects of the drug on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of mesalamine to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for mesalamine and any potential adverse effects on the breastfed child from mesalamine or from the underlying maternal condition. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>
                        </paragraph>
                        <paragraph>Advise the caregiver to monitor the breastfed infant for diarrhea. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>In published lactation studies, maternal mesalamine doses from various oral and rectal formulations and products ranged from 500 mg to 4.8 g daily. The average concentration of mesalamine in milk ranged from non-detectable to 0.5 mg/L. The average concentration of N-acetyl-5-aminosalicylic acid in milk ranged from <br/> 0.2 mg/L to 9.3 mg/L. Based on these concentrations, estimated infant daily dosages for an exclusively breastfed infant are 0 mg/kg/day to 0.075 mg/kg/day (RID 0% to 0.1%) of mesalamine and 0.03 mg/kg/day to 1.4 mg/kg/day of N-acetyl-5-aminosalicylic acid.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_246c6b77-cecf-4a13-9746-827448184908">
                     <id root="f996a4a5-b38d-4eea-ba01-ed8d1bcc2a41"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of mesalamine have been established for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. Use of mesalamine in this population is supported by evidence from adequate and well-controlled trials in adults, a multicenter, randomized, double-blind, parallel group trial in 105 pediatric patients 5 to 17 years of age, and additional pharmacokinetic analyses. The safety profile in pediatric patients was similar to that observed in adults <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_28536af0-f3bb-467b-ab42-6ee1a3b59461">6.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_618cf8e2-ee7b-4241-a4bb-610f05fa3416">12.3</linkHtml>), Clinical Studies (<linkHtml href="#www.splportal.comLINK_c10e39db-a6fe-4e9c-b720-60b58dc521ee">14.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of mesalamine have not been established in patients weighing less than 24 kg.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b24e8ccc-ad42-4eb6-bf6a-68f72bd21d00">
                     <id root="e6d87051-12fc-4a45-81f0-7203542d567f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical trials of mesalamine did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of blood dyscrasias (i.e., agranulocytosis, neutropenia, and pancytopenia) in patients who were 65 years or older who were taking mesalamine-containing products such as mesalamine delayed-release tablets compared to younger patients. Monitor complete blood cell counts and platelet counts in elderly patients during treatment with mesalamine.</paragraph>
                        <paragraph>Systemic exposures are increased in elderly subjects <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_618cf8e2-ee7b-4241-a4bb-610f05fa3416">12.3</linkHtml>)]. </content>
                        </paragraph>
                        <paragraph>In general, consider the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients when prescribing mesalamine. Consider starting at the low end of the dosing range for induction in elderly patients <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_40adab2c-116a-4eb4-b62e-a033fad0cc03">8.6</linkHtml>)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_40adab2c-116a-4eb4-b62e-a033fad0cc03">
                     <id root="0b8cb595-b1c6-4701-b1de-c9d41b08da9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Mesalamine is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Evaluate renal function in all patients prior to initiation and periodically while on mesalamine therapy. Monitor patients with known renal impairment or history of renal disease or taking nephrotoxic drugs for decreased renal function and mesalamine-related adverse reactions. Discontinue mesalamine if renal function deteriorates while on therapy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>), Adverse Reactions (<linkHtml href="#www.splportal.comLINK_88415080-889c-487e-9988-7a3b0fb3036f">6.2</linkHtml>), Drug Interactions (<linkHtml href="#www.splportal.comLINK_c2007783-4b65-4436-8554-b474a37c113a">7.1</linkHtml>)]</content>.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f04b9672-caab-4ef7-a47f-90bd9dd2961f">
               <id root="f3096e2d-5ffb-4bf4-90f4-d8ddf6b114a2"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10	OVERDOSAGE</title>
               <text>
                  <paragraph>Mesalamine is an aminosalicylate, and symptoms of salicylate toxicity may include nausea, vomiting, abdominal pain, tachypnea, hyperpnea, tinnitus, and neurologic symptoms (headache, dizziness, confusion, seizures). Severe intoxication with salicylates may lead to electrolyte and blood pH imbalance, and potentially end organ (e.g., renal and liver) damage.</paragraph>
                  <paragraph>There is no specific known antidote for mesalamine overdose; however, conventional therapy for salicylate toxicity may be beneficial in the event of acute overdosage and may include gastrointestinal tract decontamination to prevent further absorption. Correct fluid and electrolyte imbalance by the administration of appropriate intravenous therapy and maintain adequate renal function.</paragraph>
                  <paragraph>Mesalamine is a pH-dependent, delayed-release product and this factor should be considered when treating a suspected overdose.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_1e9604e1-48c5-4b27-b9e9-5e728bd79181">
               <id root="d2768a8b-8fa5-4fc1-a90d-81e49819e27e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Each mesalamine delayed-release tablet, USP for oral administration contains 1.2 g 5-aminosalicylic acid (5-ASA; mesalamine, USP), an anti-inflammatory agent. Mesalamine, USP also has the chemical name 5-amino-2-hydroxybenzoic acid and its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>The tablet is coated with a pH-dependent polymer film, which breaks down at or above pH 6.8, normally in the terminal ileum where mesalamine, USP then begins to be released from the tablet core<content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>The inactive ingredients of mesalamine delayed-release tablets, USP are ammonium hydroxide, colloidal silicon dioxide, copovidone, iron oxide black, iron oxide red, iron oxide yellow, magnesium stearate, methacrylic acid and methyl methacrylate copolymer, microcrystalline cellulose, polyethylene glycol 3350, polyvinyl alcohol, povidone, propylene glycol, shellac, sodium starch glycolate (type A), talc, titanium dioxide and triethyl citrate.</paragraph>
                  <paragraph>Meets USP Dissolution Test 3. </paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a3c6cff8-45d4-4aa1-8b85-402eea3c4175">
               <id root="6e2e3124-50b8-404a-af44-567f0b3928d1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="LINK_1e42fa04-1f4f-4310-9501-54a5275e5768">
                     <id root="aa13531c-1880-4a38-a7e0-841ff6d4ed5b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism of action of mesalamine is not fully understood, but it appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_618cf8e2-ee7b-4241-a4bb-610f05fa3416">
                     <id root="34af5141-25a0-4b71-9e54-08f11a843203"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Absorption</content>
                        </paragraph>
                        <paragraph>The total absorption of mesalamine from mesalamine delayed-release tablets 2.4 g or 4.8 g given once daily for 14 days to healthy subjects was found to be approximately 21% to 22% of the administered dose.</paragraph>
                        <paragraph>Gamma-scintigraphy studies have shown that a single dose of mesalamine delayed-release tablets 1.2 g (one tablet) passed intact through the upper gastrointestinal tract of fasted healthy subjects. Scintigraphic images showed a trail of radio-labeled tracer in the colon, suggesting that mesalamine had distributed through this region of the gastrointestinal tract.</paragraph>
                        <paragraph>In a single-dose study, mesalamine delayed-release tablets 1.2 g, 2.4 g, and 4.8 g were administered in the fasted state to healthy subjects. Plasma concentrations of mesalamine were detectable after 2 hours and reached a maximum by 9 to 12 hours on average for the doses studied. The pharmacokinetic parameters are highly variable among subjects (Table 4). Mesalamine systemic exposure in terms of area under the plasma concentration-time curve (AUC) was slightly more than dose proportional between 1.2 g and 4.8 g mesalamine delayed-release tablets. Maximum plasma concentrations (C<sub>max</sub>) of mesalamine increased approximately dose proportionately between 1.2 g and 2.4 g and sub-proportionately between 2.4 g and 4.8 g of mesalamine delayed-release tablets, with the dose normalized value at 4.8 g representing, on average, 74% of that at 2.4 g based on geometric means.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 4: Mean (SD) Pharmacokinetic Parameters for Mesalamine Following Single-Dose Administration of Mesalamine Under Fasting Conditions</caption>
                           <col width="175px"/>
                           <col width="151px"/>
                           <col width="151px"/>
                           <col width="151px"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Parameter<sup>*</sup> of Mesalamine</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Mesalamine 1.2 g</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=47)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Mesalamine 2.4 g</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=48)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Mesalamine 4.8 g</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=48)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>AUC<sub>0-t </sub>(ng·h/mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9039<sup>†</sup> (5054)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>20538 (12980)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>41434 (26640)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>AUC<sub>0-</sub>
                                       <sub>∞ </sub>(ng·h/mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9578<sup>‡</sup> (5214)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>21084 (13185)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>44775<sup>§</sup> (30302)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>C<sub>max</sub> (ng/mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>857 (638)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1595 (1484)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2154 (1140)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>T<sub>max</sub>
                                       <sup>¶</sup> (h)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9.0<sup># </sup>(4.0 to 32.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12.0 (4.0 to 34.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12.0 (4.0 to 34.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>T<sub>lag</sub>
                                       <sup>¶</sup> (h)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.0<sup>#</sup> (0 to 8.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.0 (1.0 to 4.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2.0 (1.0 to 4.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>T<sub>1/2</sub> (h) (Terminal Phase)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8.56<sup>‡</sup> (6.38)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7.05<sup>Ϸ</sup> (5.54)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7.25<sup>§</sup> (8.32)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <paragraph>
                                       <sup>*</sup>Arithmetic mean of parameter values are presented except for T<sub>max </sub>and T<sub>lag.</sub>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <paragraph>
                                       <sup>†</sup>N=43, <sup>‡</sup>N=27, <sup>§</sup>N=36, <sup>¶</sup>Median (min, max), <sup>#</sup>N=46, <sup>Ϸ</sup>N=33</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Food Effects</content>
                        </paragraph>
                        <paragraph>Administration of a single dose of mesalamine 4.8 g with a high-fat meal resulted in further delay in absorption, and plasma concentrations of mesalamine were detectable 4 hours following dosing. However, a high-fat meal increased systemic exposure of mesalamine (mean C<sub>max</sub>: increased 91%; mean AUC: increased 16%) compared to results in the fasted state. Mesalamine was administered with food in the controlled clinical trials <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)]</content>.</paragraph>
                        <paragraph>In a single- and multiple-dose pharmacokinetic study of mesalamine, 2.4 g or 4.8 g was administered once daily with standard meals to 28 healthy subjects per dose group. Plasma concentrations of mesalamine were detectable after 4 hours and were maximal by 8 hours after the single dose. Steady state was achieved generally by 2 days after dosing. Mean AUC at steady state was only modestly greater (1.1- to 1.4­fold) than predictable from single dose pharmacokinetics.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Mesalamine is approximately 43% bound to plasma proteins at the concentration of 2.5 mcg/mL.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>The only major metabolite of mesalamine (5-aminosalicylic acid) is N-acetyl-5-aminosalicylic acid. Its formation is brought about by N-acetyltransferase (NAT) activity in the liver and intestinal mucosa cells, principally by NAT-1.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Excretion of mesalamine is mainly via the renal route following metabolism to N-acetyl-5-aminosalicylic acid (acetylation); however, there is also limited excretion of the parent drug in urine. Of the approximately 21% to 22% of the dose absorbed, less than 8% of the dose was excreted unchanged in the urine after 24 hours, compared with greater than 13% for N-acetyl-5-aminosalicylic acid. The mean renal clearance (CL<sub>R</sub>) in adults ranged from 1.8 L/h to 2.9 L/h following single dose administration and ranged from 5.5 L/h to 6.4 L/h after a multiple dosing for 14 days. The apparent terminal half-lives for mesalamine and its major metabolite after administration of mesalamine 2.4 g and 4.8 g were, on average, 7 to 9 hours and 8 to 12 hours, respectively.</paragraph>
                        <paragraph>Systemic exposures in adult subjects were inversely correlated with renal function as assessed by estimated creatinine clearance <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_40adab2c-116a-4eb4-b62e-a033fad0cc03">8.6</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients</content>
                        </paragraph>
                        <paragraph>In a single-dose pharmacokinetic study of mesalamine, 4.8 g was administered in the fasted state to 71 healthy male and female subjects (28 young (18 to 35 years); 28 elderly (65 to 75 years); 15 elderly (&gt;75 years)). Increased age resulted in increased systemic exposure (approximately 2-fold in C<sub>max</sub>) to mesalamine and its metabolite N-acetyl-5-aminosalicylic acid. Increased age resulted in a slower apparent elimination of mesalamine, though there was high between-subject variability.</paragraph>
                        <table width="800px" cellpadding="5">
                           <caption>Table 5: Mean (SD) Pharmacokinetic Parameters for Mesalamine Following Single-Dose Administration of Mesalamine 4.8 g under Fasting Conditions to Young and Elderly Subjects</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Parameter of 5-ASA</content>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                       <content styleCode="bold">Young Subjects</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(18 to 35 years)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=28)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                       <content styleCode="bold">Elderly Subjects</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(65 to 75 years)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=28)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 
            <paragraph>
                                       <content styleCode="bold">Elderly Subjects</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(75 years and older)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N=15)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> AUC<sub>0-t </sub>(ng·h/mL)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 51570 (23870)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 73001 (42608)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 65820 (25283)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> AUC<sub>0-∞</sub> (ng·h/mL)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 58057<sup>*</sup> (22429)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 89612<sup>†</sup> (40596)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 63067<sup>‡</sup> (22531)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> C<sub>max</sub> (ng/mL)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2243 (1410)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4999 (4381)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4832 (4383)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> t<sub>max</sub> <sup>§</sup> (h)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 22.0 (5.98 to 48.0)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12.5 (4.00 to 36.0)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 16.0 (4.00 to 26.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> t<sub>lag</sub> <sup>§</sup> (h)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (1 to 6)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (1 to 4)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (2 to 4)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> t<sub>1/2</sub> (h), terminal phase</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5.68<sup>*</sup> (2.83)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 9.68<sup>†</sup> (7.47)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8.67<sup>‡ </sup>(5.84)</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule"> Renal clearance (L/h)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2.05 (1.33)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2.04 (1.16)</td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2.13 (1.20)</td>
                              </tr>
                              <tr>
                                 <td colspan="4"> Arithmetic mean (SD) data are presented, N = Number of subjects; 5-ASA = 5-aminosalicylic acid
            <paragraph>
                                       <sup>*</sup>N=15, <sup>†</sup>N=16, <sup>‡</sup>N=13, <sup>§</sup>Median (min-max)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>In pediatric patients 5 years to 17 years of age diagnosed with ulcerative colitis, systemic exposure of mesalamine, as measured by mean AUC<sub>ss</sub> and C<sub>max,ss</sub>, increased in a dose-proportional manner between 30 and 60 mg/kg/day of mesalamine and increased in a sub-proportional between 60 and 100 mg/kg/day doses. Pharmacokinetic parameters had moderate to high inter-subject variability with CV% ranging from 36% to 52% in pediatric patients.</paragraph>
                        <paragraph>The overall systemic exposure of mesalamine following oral administration of 4.8 g once daily for 7 days in a limited number of pediatric patients 5 years to 17 years of age (AUC range of 30,556 to 50,388 ng·hr/mL, n=3) was in similar range to that was observed in the healthy adults (AUC of 41,434 ± 26,640 ng·hr/mL, n=48) after single dose administration.</paragraph>
                        <paragraph> The mean renal clearance (CL<sub>R</sub>) of mesalamine in pediatric patients (range from approximately 5.0 to 6.5 L/h) seems to be similar to that observed with healthy adult subjects after multiple dose administration.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>The potential effect of mesalamine (4.8 g given once daily) on the pharmacokinetics of four commonly used antibiotics were evaluated in healthy subjects. The four antibiotics studied and their dosing regimens were as follows: amoxicillin (single 500 mg dose), ciprofloxacin XR (single 500 mg dose), metronidazole (750 mg twice daily for 3.5 days), and sulfamethoxazole/trimethoprim (800 mg/160 mg twice daily for 3.5 days). The change in C<sub>max</sub> and AUC of amoxicillin, ciprofloxacin, and metronidazole when they were co-administered with mesalamine were all 3% or less. There was an increase of 12% in C<sub>max</sub> and an increase of 15% in AUC of sulfamethoxazole when sulfamethoxazole/trimethoprim was coadministered with mesalamine. Coadministration of mesalamine did not result in clinically significant changes in the pharmacokinetics of any of the four antibiotics.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_85b81f4f-a306-492b-94e5-9b4bfb3cdcc5">
               <id root="54ded27c-f021-4005-acbc-1777855507ff"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="LINK_e5698440-b7e8-4aa5-82ac-3ef37f3df9cc">
                     <id root="2a6b80e7-1c06-429d-a980-ec4704644096"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a 104-week dietary carcinogenicity study in CD-1 mice, mesalamine at doses up to 2,500 mg/kg/day was not tumorigenic. This dose is 2.2 times the maximum recommended human dose (based on a body surface area comparison) of mesalamine. Furthermore, in a 104-week dietary carcinogenicity study in Wistar rats, mesalamine up to a dose of 800 mg/kg/day was not tumorigenic. This dose is 1.4 times the recommended human dose (based on a body surface area comparison) of mesalamine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>No evidence of mutagenicity was observed in an <content styleCode="italics">in vitro</content> Ames test or an <content styleCode="italics">in vivo </content>mouse micronucleus test.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>No effects on fertility or reproductive performance were observed in male or female rats at oral doses of mesalamine up to 400 mg/kg/day (0.7 times the maximum recommended human dose based on a body surface area comparison).</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_521db0db-ac99-4e31-ae36-5e2c99602b4a">
                     <id root="3b3fb481-8244-453a-8bc0-6b9a36c99762"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2	Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In animal studies with mesalamine, a 13-week oral toxicity study in mice and 13-week and 52-week oral toxicity studies in rats and cynomolgus monkeys have shown the kidney to be the major target organ of mesalamine toxicity. Oral daily doses of 2,400 mg/kg in mice and 1,150 mg/kg in rats produced renal lesions including granular and hyaline casts, tubular degeneration, tubular dilation, renal infarct, papillary necrosis, tubular necrosis, and interstitial nephritis. In cynomolgus monkeys, oral daily doses of 250 mg/kg or higher produced nephrosis, papillary edema, and interstitial fibrosis.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_84c75c0f-1249-4db9-adcc-4fa4a4c74533">
               <id root="90633992-8582-41e2-9329-552b96dade47"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="LINK_14625eff-0d66-4d9f-9a29-601254cd684b">
                     <id root="a90c44e2-be0a-4a98-88ec-32a2df66e661"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Adults with Mildly to Moderately Active
Ulcerative Colitis</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Induction of Remission </content>
                        </paragraph>
                        <paragraph>Two similarly designed, randomized, double-blind, placebo-controlled trials (Study 1, NCT00503243 and Study 2, NCT00548574) were conducted in 517 adult patients with mildly to moderately active ulcerative colitis. The study population was primarily Caucasian (80%), had a mean age of 42 years (6% age 65 years or older), and was approximately 50% male. Both studies used mesalamine dosages of 2.4 g and 4.8 g administered once daily for 8 weeks, except in Study 1 the 2.4 g  dosage was administered as two divided doses (i.e., 1.2 g twice daily). The primary efficacy endpoint in both trials was to compare the percentage of patients in remission after 8 weeks of treatment for the mesalamine treatment groups versus placebo. Remission was defined as an Ulcerative Colitis Disease Activity Index (UC-DAI) of ≤1, with scores of zero for rectal bleeding and for stool frequency, and a sigmoidoscopy score reduction of 1 point or more from baseline.</paragraph>
                        <paragraph>In both studies, the mesalamine dosages of 2.4 g and 4.8 g once daily demonstrated superiority over placebo in the primary efficacy endpoint (Table 6). Both mesalamine dosages also provided consistent benefit in secondary efficacy parameters, including clinical improvement, clinical remission, and sigmoidoscopic improvement. Both mesalamine dosages had similar efficacy profiles.<br/>
                        </paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 6: Proportion of Adult Patients with Mildly to Moderately Active Ulcerative Colitis in Remission at Week 8 in Two Double-Blind Placebo-Controlled Induction Trials</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Study 1</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=262)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n/N (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Study 2</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=255)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">n/N (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Mesalamine 2.4 g/day</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>30/88 (34)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>34/84 (41)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Mesalamine 4.8 g/day</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>26/89 (29)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>35/85 (41)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Placebo</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>11/85 (13)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>19/86 (22)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Maintenance of Remission</content>
                           <br/>
                        </paragraph>
                        <paragraph>A multicenter, randomized, double-blind, active comparator study (Study 3, NCT00151892) was conducted in a total of 826 adult patients in remission from ulcerative colitis. Patients were randomized in a 1:1 ratio to receive either mesalamine delayed-release 2.4 g administered once daily or another mesalamine delayed-release product administered as 0.8 g twice daily. The study population had a mean age of 45 years (8% age 65 years or older), were 52% male, and were primarily Caucasian (64%).</paragraph>
                        <paragraph>Maintenance of remission was assessed using a modified UC-DAI. For this trial, maintenance of remission was based on maintaining endoscopic remission defined as a modified UC-DAI endoscopy subscore of ≤1. An endoscopy subscore of 0 represented normal mucosal appearance with intact vascular pattern and no friability or granulation. For this trial the endoscopy score definition of 1 (mild disease) was modified such that it could include erythema, decreased vascular pattern, and minimal granularity; however, it could not include friability.<br/>
                        </paragraph>
                        <paragraph>The proportion of patients who maintained remission at Month 6 in this study using mesalamine delayed-release 2.4 g once daily (84%) was similar to the comparator (82%).</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c10e39db-a6fe-4e9c-b720-60b58dc521ee">
                     <id root="c25f9820-f812-42e8-b203-b6b37175e6ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Pediatric Patients with Mildly to Moderately Active Ulcerative Colitis Weighing at Least 24 kg</title>
                     <text>
                        <paragraph>A multicenter, randomized, double-blind, parallel-group study (NCT02093663) was conducted in pediatric patients aged 5 through 17 years with mildly to moderately active ulcerative colitis to determine the safety and effectiveness of mesalamine. The study consisted of two treatment phases, an initial 8-week phase and a 26-week phase. The overall population consisted of 105 patients, of whom 27 patients participated in both the 8-week and 26-week phases.</paragraph>
                        <paragraph>Each phase included two dosage arms and patients were randomized at the beginning of each phase in a 1:1 ratio, stratified by body weight group. Patients received a low or a high weight-based dosage of mesalamine in four weight groups. Because of the small number of patients in the lowest body weight group (0 in the 8-week phase and 3 in the 26-week phase), the safety and effectiveness of mesalamine in patients weighing less than <br/> 24 kg have not been established.</paragraph>
                        <paragraph>Patients were eligible for the initial 8-week phase if they had mildly to moderately active ulcerative colitis as defined by the UC-DAI score of at least 4 with an endoscopic subscore of 2 or 3.</paragraph>
                        <paragraph>In the 53 patients enrolled in the initial phase, the mean age and weight of patients was 14 years and 53 kg, the mean (SD) baseline UC-DAI score was 5.8 (1.8), 93% were white, and 59% were male. The primary endpoint was defined by the partial UC-DAI less than or equal to 1 (with rectal bleeding equal to 0, stool frequency less than or equal to 1, and Physician’s Global Assessment [PGA] equal to 0). Of the 26 patients in the recommended mesalamine dosage arm, 65% achieved the primary endpoint after 8 weeks of treatment. During the initial 8-week phase, fewer patients who received the recommended mesalamine dosage were discontinued from the study due to ulcerative colitis (0/26, 0%) compared to patients who received a lower than recommended mesalamine dosage (8/27, 30%).</paragraph>
                        <paragraph>Patients who met the primary endpoint at 8 weeks were eligible to continue treatment in the 26-week phase. Patients were also eligible to enter the 26-week phase without having participated in the 8-week phase if they had a UC-DAI score of less than or equal to 2 with an endoscopic subscore of 0 or 1 (modified to exclude friability).</paragraph>
                        <paragraph>There were 87 patients enrolled in the 26-week phase. The mean age and weight of patients were 14 years and 54 kg; 97% were white and 55% were female. Of the 42 patients in the recommended mesalamine dosage arm, 55% achieved the primary endpoint, which was defined the same as in the 8-week phase. In the 26-week phase, the arm with a higher than recommended mesalamine dosage was not more effective and is not recommended <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_2001787b-c48c-43e2-86eb-a383054f1ec1">2</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Endpoints</content>
                        </paragraph>
                        <paragraph> Clinical remission, defined by a Mayo stool frequency subscore equal to 0 or 1, Mayo rectal bleeding subscore equal to 0, and a Mayo endoscopic subscore equal to 0 or 1 (modified to exclude friability) or 0 on the UC-DAI, was determined for patients with available endoscopic assessment after completion of the 26-week phase. Patients without endoscopic data at week 26 were assumed not to have achieved clinical remission. Of the 42 patients in the recommended mesalamine dosage arm, 36% achieved clinical remission. Clinical remission could not be assessed in the initial 8-week phase because there were too few patients who underwent endoscopy.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ca11c243-b23d-4a46-bc24-9c69581e3923">
               <id root="215a83fb-e7ec-44bc-9ed4-bd796a9097cd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Mesalamine delayed-release tablets, USP are available as red-brown, oval shaped, coated tablets containing 1.2 g mesalamine, USP and imprinted with “<content styleCode="bold">WPI 2245</content>” in black ink on one side and plain on the other side.</paragraph>
                  <paragraph>NDC 0591-2245-22 (Bottle of 120)</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_78313003-d846-4a59-8b66-ff81694aaac4">
               <id root="a69debdb-c6e7-418d-a642-a1e5ddc94f02"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Renal Impairment</content>
                  </paragraph>
                  <paragraph>Inform patients that mesalamine delayed-release tablets may decrease their renal function, especially if they have known renal impairment or are taking nephrotoxic drugs, and periodic monitoring of renal function will be performed while they are on therapy. Advise patients to complete all blood tests ordered by their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_416f1d5a-5535-4729-9407-5f4a1ce55a91">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Mesalamine-Induced Acute Intolerance Syndrome and Other Hypersensitivity Reactions </content>
                  </paragraph>
                  <paragraph>Instruct patients to stop taking mesalamine delayed-release tablets and report to their healthcare provider if they experience new or worsening symptoms of acute intolerance syndrome (cramping, abdominal pain, bloody diarrhea, fever, headache, and rash) or other symptoms suggestive of mesalamine-induced hypersensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_69f9eecd-e0d2-493d-88e8-47ea95ca44a4">5.2</linkHtml>, <linkHtml href="#www.splportal.comLINK_77245a53-50d3-42e8-a043-e9202711b091">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatic Failure</content>
                  </paragraph>
                  <paragraph>Advise patients with known liver disease to contact their healthcare provider if they experience signs or symptoms of worsening liver function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_9269061b-686e-453d-8fbb-25b501e75dff">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Severe Cutaneous Adverse Reactions</content>
                  </paragraph>
                  <paragraph> Inform patients of the signs and symptoms of severe cutaneous adverse reactions. Instruct patients to stop taking mesalamine delayed-release tablets and report to their healthcare provider at first appearance of a severe cutaneous adverse reaction or other sign of hypersensitivity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_4ab65921-2858-423a-bd98-39f3702c03c0">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Upper Gastrointestinal Tract Obstruction</content>
                  </paragraph>
                  <paragraph>Advise patients to contact their healthcare provider if they experience signs and symptoms of upper gastrointestinal tract obstruction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7ea758a3-f44f-4eb8-afeb-0da59787fca7">5.6</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Photosensitivity</content>
                  </paragraph>
                  <paragraph>Advise patients with pre-existing skin conditions to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7eefc9a2-09ca-4d84-91d1-6a26feccc7fa">5.7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Nephrolithiasis</content>
                  </paragraph>
                  <paragraph>Instruct patients to drink an adequate amount of fluids during treatment in order to minimize the risk of kidney stone formation and to contact their healthcare provider if they experience signs or symptoms of a kidney stone (e.g., severe side or back pain, blood in the urine) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Blood Disorders</content>
                  </paragraph>
                  <paragraph>Inform elderly patients and those taking azathioprine or 6-mercaptopurine of the risk for blood disorders and the need for periodic monitoring of complete blood cell counts and platelet counts while on therapy. Advise patients to complete all blood tests ordered by their healthcare provider <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_64c59764-d7eb-442d-a823-6b1b491340ac">7.2</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_b24e8ccc-ad42-4eb6-bf6a-68f72bd21d00">8.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration<br/>
                     </content>Instruct patients:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Swallow mesalamine delayed-release tablets whole; do not split or crush. </item>
                     <item>Take mesalamine delayed-release tablets with food <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_618cf8e2-ee7b-4241-a4bb-610f05fa3416">12.3</linkHtml>)]</content>.</item>
                     <item>Urine may become discolored reddish-brown while taking mesalamine delayed-release tablets when it comes in contact with surfaces or water treated with hypochlorite-containing bleach. If discolored urine is observed, advise patients to observe their urine flow. Report to the healthcare provider only if urine is discolored on leaving the body, before contact with any surface or water (e.g., in the toilet).</item>
                     <item>Drink an adequate amount of fluids <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_6ffce658-783e-482e-94a9-a9c52c855eca">5.8</linkHtml>)]</content>. </item>
                  </list>
                  <paragraph>Manufactured For:<br/>
                     <content styleCode="bold">Teva Pharmaceuticals<br/>
                     </content>Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. K 3/2025</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3de0daf0-cd03-4000-aef5-6f6f469e776d">
               <id root="fafeeef9-9273-48a2-81ae-6ac132403c49"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0591-2245-22</paragraph>
                  <paragraph>(Once Daily)</paragraph>
                  <paragraph>Mesalamine Delayed-Release Tablets, USP<br/>
                     <br/>
1.2 gram</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>120 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>